ArticleMedicine2026
The HALP score is a novel prognostic biomarker in multiple myeloma: A retrospective cohort study of 450 patients.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study aimed to evaluate the prognostic significance of hemoglobin, albumin, lymphocyte, and platelet (HALP) levels at diagnosis in patients with multiple myeloma (MM). We retrospectively analyzed 450 patients diagnosed with MM between 2008 and 2023. The HALP score was calculated using pretreatment laboratory values of hemoglobin, albumin, lymphocytes, and platelets. Patients were categorized into the high and low HALP groups. Survival outcomes were analyzed using the Kaplan-Meier and Cox regression methods. Patients with HALP ≤ 27.68 had a significantly lower overall survival (OS) (median 50 vs 79 months, P < .001). Patients with low HALP scores had significantly shorter median OS and progression-free survival than those with high HALP scores (P < .001). In the multivariate analysis, HALP ≤ 27.68 was independently associated with increased mortality risk (hazard ratio: 1.74; 95% confidence interavl: 1.32-2.29). The HALP score remained an independent predictor of OS. The HALP score is a useful, accessible, and cost-effective prognostic marker for MM, and may aid in risk stratification.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.